There have been 34 cases of high level azithromycin resistant gonorrhoea amongst residents of England between November 2014 and April 2016. The outbreak spread from the north of England to the West Midlands and south of England, including London. Initial cases were among heterosexuals but more recent evidence suggests high level azithromycin resistant gonorrhoea is now spreading among men who have sex with men.
15 April 2016 | Public Health England
Herbal medicine use among HIV positive people in Nigeria is widespread, poorly recorded and often precedes ART initiation. Contamination with antiretrovirals is possible and concerning, particularly in untreated people, say the authors of a study of herbal medicine presented at CROI 2016.
24 March 2016 | HIV i-Base
At CROI today, researchers and providers heard a detailed case study of a man who was infected with drug-resistant HIV while taking PrEP. No study to date has definitively documented a “breakthrough” HIV infection during PrEP with adherence to Truvada, so the report has garnered a lot of attention and concern from community members. We spoke with Robert Grant, MD, MPH, to give context to the discussion about what this case means for people currently taking PrEP.
26 February 2016 | BETA blog
Drug “tails” are a hot topic at CROI 2016 as attendees wait to hear results from a long-acting cabotegravir PrEP injection study with HIV-negative men. A few prominent researchers have already incorporated the issue of drug “tails” into their discussions of one potential downside to having a PrEP drug that stays in a person’s system for an extended length of time.
25 February 2016 | BETA blog
A recent study found more resistance to the antiretroviral medicine tenofovir than had previously been reported, with 20% resistance to tenofovir in patients with treatment failure in Europe and over 50% resistance in patients with treatment failure in sub-Saharan Africa... The study underlines the importance of rapidly identifying treatment failure through routine measurement of viral load suppression—this is the basis of the third pillar of UNAIDS’ 90–90–90 treatment target, that 90% of people accessing HIV treatment have suppressed viral loads.
09 February 2016 | UNAIDS
Resistance to a key HIV drug is common worldwide and could mean trouble for treating and preventing the virus that causes AIDS, according to a new study.
29 January 2016 | Reuters
Even people who are adherent to their medication regimens may experience occasional “blips” in their viral loads, experience viral rebound or maintain a steady, if low, viral load above undetectable levels. To understand why some people struggle to achieve or remain undetectable, we spoke with Keith Henry, MD, an HIV specialist at Hennepin County Medical Center who has more than 25 years of experience caring for people with HIV.
06 January 2016 | BETA blog
An outbreak of highly drug-resistant gonorrhoea has been detected in the north of England, triggering a national alert. Fifteen cases, all in heterosexuals, have been detected by Public Health England (PHE) so far, the British Association for Sexual Health and HIV said.
18 September 2015 | Daily Telegraph
Sexual health care in the UK has traditionally centred on specialist GUM (genito-urinary medicine) services. Since the turn of the twenty-first century primary care has played an increasing role, however. The 2012 Health and Social Care Act is in line with this tendency, with most GP practices now being commissioned to provide level 1 STI screening. Questions have recently been raised about the conformity of care provided by GPs to national guidelines, established for the UK by the British Association for Sexual Health and HIV. In a world where Gonorrhoea – and perhaps one day Chlamydia – is set to become increasingly hard to treat, the problem of ensuring the conformity of generalists to universal standards of treatment is unlikely to go away.
26 August 2015 | BMJ
Recent data suggested that retreatment HIV drug resistance in sub-Saharan Africa was associated with a nearly fourfold increase in switching to second-line ART, but did not influence mortality or AIDS-related events.
11 August 2015 | Healio